$JNJ (Johnson & Johnson)

$JNJ {{ '2016-01-26T12:32:29+0000' | timeago}} • Announcement

Healthcare giant $JNJ reported a 2.4% decline in 4Q15 sales due to strong U.S. dollar, despite a rise in earnings. Net income rose to $3.22Bil or $1.15 per share from $2.52Bil or $0.89 per share last year. Sales fell to $17.81Bil from $18.25Bil. Adjusted EPS increased 5.1% to $1.44.

$JNJ {{ '2018-01-23T20:22:09+0000' | timeago}} • Webcast

$JNJ said its best-selling Remicade, a drug for rheumatoid arthritis, fell almost 10% in 4Q17, hurt by stiff competition from biosimilars. Meanwhile, sale of consumer health products increased over 3% during the quarter.

$JNJ {{ '2018-01-23T20:02:58+0000' | timeago}} • Webcast

$JNJ said that it has approx $16Bil in cash accumulated in foreign markets. The pharma giant added that it plans to immediately transfer $12Bil of this amount into the country, to fund its US operations and also pay debts.

$JNJ {{ '2018-01-23T13:43:35+0000' | timeago}} • Announcement

$JNJ expects sales of $80.6Bil to $81.4Bil in FY18, reflecting expected operational growth in the range of 3.5% to 4.5%. Adjusted EPS for this period is estimated to be $8.00 to $8.20.

$JNJ {{ '2018-01-23T13:40:35+0000' | timeago}} • Announcement

Pharma giant $JNJ swung to a loss of $10.7Bil, or $3.99 per share in 4Q17, driven by tax-related expenses of $13.6Bil. Excluding the one-time costs, net income grew 10% to $1.74 per share. Riding on double-digit growth in drug sales during the quarter, total revenue jumped 11.5% to $20.2Bil.

$JNJ {{ '2018-01-23T13:27:16+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q4 2017 Highlights

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$JNJ {{ '2017-12-21T18:10:50+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said the FDA has granted Priority Review designation for the New Drug Application (NDA) for apalutamide as treatment for non-metastatic castration-resistant prostate cancer (CRPC). This is the first agent submitted for approval to treat earlier stage castration-resistant prostate cancer at high risk for metastasis.

$MDT {{ '2017-11-22T20:29:59+0000' | timeago}} • Webcast

In Oct., Animas announced to cease the manufacture and sale of its insulin pumps and partnered with $MDT to offer its customers the opportunity to transfer to a new device.With $JNJ exiting the insulin pump market in the US and Canada, $MDT now has access to the 90,000 patients who use Animas insulin pumps.

$JNJ {{ '2017-10-27T11:25:43+0000' | timeago}} • Announcement

Janssen Pharmaceutical, a $JNJ company, said the Phase 3 AMBER study achieved its primary endpoint and showed that its investigational regimen containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg showed positive results in previously untreated HIV-1 positive adults.

$JNJ {{ '2017-10-19T14:38:55+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 4Q17 of $0.84 per share on its common stock. The dividend is payable on Dec 12, 2017 to shareholders as on Nov 28, 2017.

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$JNJ {{ '2017-10-17T19:18:23+0000' | timeago}} • Webcast

$JNJ said sale of its blockbuster drug Remicade, used in the treatment of rheumatoid-arthritis declined 7.6% to $1.6Bil in 3Q17, hurt by competition from cheaper alternatives called biosimilars. The pharma giant said it has reduced Remicade's price, in view of tight competition in the market.

$JNJ {{ '2017-10-17T18:41:27+0000' | timeago}} • Webcast

Speaking on the effect of Hurricane Maria that hit Puerto Rico last month, $JNJ said all six of its plants on the island are making and shipping drugs using energy from generators. Though the company said intermittent shortage of drugs cannot be ruled out, it added that it does not see any material impact of the hurricane on future results.

$JNJ {{ '2017-10-17T13:40:49+0000' | timeago}} • Webcast

Only months after promising investors a slew of new blockbuster drugs, $JNJ said it has decided to discontinue clinical trials for two of its drugs. Sirukumab, for the treatment of rheumatoid arthritis, and talacotuzumab, for the treatment of myeloid leukemia, are the drugs that have been discontinued.

$JNJ {{ '2017-10-17T12:09:28+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q3 2017 Highlights

$JNJ {{ '2017-10-17T11:47:16+0000' | timeago}} • Announcement

$JNJ raised its sales and adjusted earnings guidance for FY17. The New Brunswick, NJ-based healthcare giant now expects sales for the period to be in the range of $76.1 - 76.5Bil, verses the prior guidance of $75.8 - 76.1Bil. Adjusted earnings is anticipated to be $7.25 - $7.30 per share, compared to the prior guidance of $7.12 - $7.22 per share.

$JNJ {{ '2017-10-17T11:36:50+0000' | timeago}} • Announcement

Kicking off the earnings season in healthcare sector, $JNJ reported 10.3% growth in its sales to $19.7Bil in 3Q17. Adjusted earnings also rose double digits to $5.2Bil, or $1.90 per share, driven by strong growth in Pharma unit, as well as Actelion acquisition. On a GAAP basis, earnings fell 12% to $3.8Bil, or $1.37 per share.

$JNJ {{ '2017-10-16T14:43:30+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech Inc. has received FDA approval for an expanded indication for STELARA for the treatment of adolescents with plaque psoriasis.

$JNJ {{ '2017-10-05T13:58:49+0000' | timeago}} • Announcement

Animas Corp., a $JNJ Diabetes Care Companies, plans to discontinue the manufacturing and sale of Animas Vibe and OneTouch Ping insulin pumps, close operations and exit the insulin pump business. Animas has selected $MDT as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers.

$JNJ {{ '2017-10-02T21:24:15+0000' | timeago}} • Announcement

$JNJ completed divestiture of its Codman Neurosurgery business to $IART for about $1.045Bil. The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neuro intensive care and cranial surgery, and generated net revenues of about $371.5MM in 2016.

Recent Transcripts

JNJ (Johnson & Johnson)
Tuesday, January 23 2018 - 1:30pm
PBYI (Puma Biotechnology, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
MGNX (MacroGenics, Inc.)
Wednesday, November 8 2017 - 9:30pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
MNKD (MannKind Corp.)
Tuesday, November 7 2017 - 10:00pm
THC (Tenet Healthcare Corp.)
Tuesday, November 7 2017 - 3:00pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
SEM (Select Medical Holdings Corporation)
Friday, November 3 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, November 2 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
MGLN (Magellan Health, Inc.)
Wednesday, November 1 2017 - 2:00pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
CYTK (Cytokinetics, Incorporated)
Thursday, October 26 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm

AlphaGraphics you may like